The medicine Mysimba can be reimbursed for the treatment of overweight from the basic package. ‘Research shows that the drug is effective in people with a Body Mass Index (BMI) of 30 or higher who already participate in a combined lifestyle intervention (GLI)’, writes the National Health Care Institute in an advisory report to the Minister of Health, Welfare and Sport.
Also working at BMI between 27 and 30
‘The drug also works for people with a BMI between 27 and 30 who participate in a GLI and who have one or more diseases that are related to overweight, such as cardiovascular disease or type 2 diabetes. The reimbursement only applies to these 2 groups, because the effect of the drug has been demonstrated on them’, according to the advice of the health care institute.
Appetite decreases due to lowering of dopamine
Mysimba is used to reduce weight when people on a low-calorie diet and more exercise do not lose enough weight. Mysimba contains 2 substances that work on the brain. Bupropion decreases the activity of dopamine, which decreases appetite. Naltrexone reduces the need to eat.
Healthcare institute: reimbursed anti-overweight medicine Mysimba from basic package
Source link Healthcare institute: reimbursed anti-overweight medicine Mysimba from basic package